Treatment Considerations With Aldosterone Receptor Antagonists

Journal of Clinical Hypertension

Volumn 13, Issue 1, 2011, Pages 65-69

  Sica, Domenic A ^a   Flack, John M ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; SPIRONOLACTONE;

DRUG EFFECT; DRUG MECHANISM; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY FUNCTION; NOTE; PRIORITY JOURNAL;

ALDOSTERONE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMEOSTASIS; HUMANS; HYPERKALEMIA; HYPERTENSION; KIDNEY; MAGNESIUM; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 78650986656     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00377.x     Document Type: Note

References (31)

1. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10:23-29.
2. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217:27-31.
3. Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005;150:426-433.
4. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-1155.
5. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
6. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther. 1979;25:33-42.
7. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
8. de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147-152.
9. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25:891-894.
10. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension. 2007;49:839-845.
11. Gaddam K, Pimenta E, Thomas SJ, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24:532-537.
12. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
13. Karagiannis A, Tziomalos K, Papageorgious A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9:509-515.
14. Jansen PM, Danser AJ, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009; 27:680-691.
15. Murdoch DL, Forrest G, Davies DL, et al. A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects. Br J Clin Pharmacol. 1993;35:373-378.
16. Dyckner T, Wester PO, Widman L. Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. Eur J Clin Pharmacol. 1986;30:535-540.
17. Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens. 2010;28:170-177.
18. Mahmud A, Mahgoub M, Hall M, et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005;18:1631-1635.
19. Ludbrook A, Dynon M, Mendelsohn FA, et al. Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension. Med J Aust. 1980;1:124-125.
20. Bell GM, Fananapazir L, Anderton JL. Comparison of single and divided daily dose spironolactone in the control of hypertension. Br J Clin Pharmacol. 1981;12:585-588.
21. Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992;102:1680-1685.
22. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2:370-376.
23. van Vliet AA, Donker AJ, Nauta JJ, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71:21A-28A.
24. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol. 2003;39:187-192.
25. Ravis WR, Reid S, Sica DA, et al. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol. 2005;45:810-821.
26. Accessed July 25, 2010.
27. Gao X, Peng L, Adhikari CM, et al. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail. 2007;13:170-177.
28. Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria [Abstract]. Am J Hypertens. 2002;15:24A.
29. Epstein M, Williams GH, Weinberger MH, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940-951.
30. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170:1045-1049.
31. Mimidis K, Papadopoulos V, Kartalis G. Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis. Scand J Gastroenterol. 2007;42:1516-1517.